Section of Pediatric and Congenital Cardiac Surgery, Division of Cardiac, Thoracic, and Vascular Surgery, New York Presbyterian-Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, NY.
Section of Pediatric and Congenital Cardiac Surgery, Division of Cardiac, Thoracic, and Vascular Surgery, New York Presbyterian-Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, NY.
J Thorac Cardiovasc Surg. 2024 Oct;168(4):1182-1191.e3. doi: 10.1016/j.jtcvs.2024.01.022. Epub 2024 Jan 22.
Autograft durability and remodeling are thought to be superior in younger pediatric patients after the Ross operation. We sought to delineate the fate of autografts across the pediatric age spectrum in patients with primary aortic stenosis (AS).
We retrospectively reviewed patients age ≤18 years with primary AS who underwent the Ross operation between 1993 and 2020. Patients were categorized by age. The primary endpoint was autograft dimensional change, and secondary endpoints were severe neo-aortic insufficiency (AI) and autograft reintervention.
A total of 119 patients underwent the Ross operation, including 37 (31.1%) in group I (age <18 months), 24 (20.2%) in group II (age 18 months-8 years), and 58 (48.7%) in group III (age 8-18 years). All groups exhibited similar annular growth rates within the first 5 postoperative years, followed by a collective decrease in annulus growth rates from year 5 to year 10. Group III experienced rapid sinus dilation in the first 5 years, followed by stabilization of the sinus z-score from year 5 to year 10, whereas groups I and II demonstrated stable sinus z-scores over 10 years. There were 4 early deaths (3.4%) and 2 late deaths (1.7%) at a median follow-up of 8.1 years (range, 0.01-26.3 years). At 15 years, the incidences of severe neo-AI (0.0 ± 0.0% vs 0.0 ± 0.0% vs 3.9 ± 3.9%; P = .52) and autograft reintervention (8.4 ± 6.0% vs 0.0 ± 0.0% vs 2.4 ± 2.4%; P = .47) were similar in the 3 groups.
Age at the time of Ross operation for primary AS does not influence long-term autograft remodeling or durability. Other physiologic or technical factors are likely greater determinants of autograft fate.
Ross 手术后,人们认为年轻的儿科患者的移植物耐久性和重塑能力更好。我们旨在描绘在患有原发性主动脉瓣狭窄(AS)的患者中,移植物在儿科年龄谱中的命运。
我们回顾性分析了 1993 年至 2020 年期间接受 Ross 手术的年龄≤18 岁的原发性 AS 患者。根据年龄将患者分为三组。主要终点是移植物的尺寸变化,次要终点是严重的新主动脉瓣关闭不全(AI)和移植物再干预。
共有 119 名患者接受了 Ross 手术,其中 I 组(<18 个月)37 例(31.1%),II 组(18 个月-8 岁)24 例(20.2%),III 组(8-18 岁)58 例(48.7%)。所有组在前 5 年的术后均表现出相似的环状生长速度,随后从第 5 年到第 10 年,环状生长速度均呈集体下降。第 III 组在最初的 5 年内快速扩张窦部,随后从第 5 年到第 10 年,窦部 z 分数稳定,而第 I 组和第 II 组在 10 年以上的时间里窦部 z 分数稳定。在中位随访 8.1 年(范围,0.01-26.3 年)期间,有 4 例早期死亡(3.4%)和 2 例晚期死亡(1.7%)。在 15 年时,三组的严重新 AI(0.0±0.0%比 0.0±0.0%比 3.9±3.9%;P=0.52)和移植物再干预(8.4±6.0%比 0.0±0.0%比 2.4±2.4%;P=0.47)的发生率相似。
Ross 手术治疗原发性 AS 时的年龄并不影响移植物的长期重塑或耐久性。其他生理或技术因素可能是移植物命运的更大决定因素。